CJC-1295 / Ipamorelin
A two-part blend pairing a GHRH analogue with a selective GH secretagogue, studied for the way the two mechanisms together amplify growth-hormone pulsatility beyond what either produces alone.
What it is
CJC-1295 / Ipamorelin is a combination of two peptides that act on the growth-hormone axis through complementary routes. CJC-1295 is a growth-hormone-releasing hormone (GHRH) analogue that drives the pituitary to release GH, while Ipamorelin is a selective GH secretagogue (a ghrelin mimetic) that triggers release through a second, independent receptor. Supplied together as a lyophilized blend, the pair is one of the most-studied secretagogue combinations in the field.
What the research looks at
Research on this blend focuses on synergy: because CJC-1295 and Ipamorelin signal through different receptors, models pairing them show GH pulsatility amplified beyond what either peptide produces on its own. Investigators study the combined pulse amplitude, the timing of release, and how the GHRH and secretagogue arms reinforce one another in the GH-IGF-1 axis. Supplied strictly for laboratory research use only, not for human or veterinary use.
At a glance
| Class | GHRH analogue + GH secretagogue blend |
| Molecular weight | 3367.9 / 711.9 Da |
| CAS | 863288-34-0 / 170851-70-4 |
| Vial | 10 mg blend (5 + 5) lyophilized |
| Availability | In stock (new) |
Preparing it
The blend ships as a lyophilized powder and is reconstituted with bacteriostatic water (or sterile water for single-session work) before use. Both peptides go into solution together; choose a volume that gives a concentration convenient to measure on a U-100 syringe. See reconstitution for the step-by-step method and the concentration formula for working out how much diluent to add.